Vyndaqel
What Vyndaqel is used for
Vyndaqel is indicated for the treatment of transthyretin amyloidosis in adult patients with stage-1 symptomatic polyneuropathy to delay peripheral neurologic impairment.
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
- Approved under exceptional circumstances: full data cannot be collected, usually because the disease is very rare.
Key facts
- Brand
- Vyndaqel
- Active substance
- tafamidis
- Disease area
- Amyloidosis
- Medicine group
- Other nervous system drugs
- ATC code
- N07XX08
- Marketing authorisation holder
- Pfizer Europe MA EEIG
- Authorised in the EU since
- 2011
Official information
In the USA
Same active substance: Vyndamax
In India
- Tafamidis: 1 brand in India
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Vyndaqel used for?
Vyndaqel is indicated for the treatment of transthyretin amyloidosis in adult patients with stage-1 symptomatic polyneuropathy to delay peripheral neurologic impairment.
What is the active substance in Vyndaqel?
Vyndaqel contains tafamidis.
Who makes Vyndaqel?
The EU marketing authorisation holder is Pfizer Europe MA EEIG.
Is Vyndaqel an orphan medicine?
Yes. Vyndaqel is designated an orphan medicine in the EU, for a rare disease (Amyloidosis).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU